\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Health Seeking Behavior, Cost of Illness and Quality of Life of Patients with COPD among 35 Years \& above Rural Population of Gurugram, Haryana}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2019 2019-01-15 (revised: 7 Year 2019 15 January 2019)} \def\TheID{\makeatother } \def\TheDate{2019 2019-01-15} \title{Health Seeking Behavior, Cost of Illness and Quality of Life of Patients with COPD among 35 Years \& above Rural Population of Gurugram, Haryana} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{Dr. Balbir Singh Deswal} \author[2]{Ankita Khokhar} \author[3]{ .} \affil[1]{ SGT University} \renewcommand\Authands{ and } \date{\small \em Received: 9 December 2018 Accepted: 1 January 2019 Published: 15 January 2019} \maketitle \begin{abstract} Background: COPD is the 4 th leading cause of death worldwide and predicted to be third by 2030. In India, COPD accounts for 7% of mortality and 3% DALYs loss.Objective: The study undertaken to assess the health seeking behaviour and cost of illness of COPD and the influence of severity of the disease over the cost and the quality of life. Materials and Methods:The study conducted in 115 patients aged 35 years and above, a rural population of Gurugram, Haryana. Cost of illness (direct and indirect costs) was calculated in Indian rupees from the expenditures of the hospital visits, pharmacotherapy, oxygen therapy, biochemical investigations, diagnostic procedures, physiotherapy and hospitalization due to acute exacerbations by patient interview and review of patient's case history, medical and billing records. Quality of life of patients in Stage III and Stage IV COPD was estimated using St. George's Respiratory Questionnaire (SGRQ) score. Data collected on structured schedule & analyzed. \end{abstract} \keywords{COPD, health behavior, medical cost, quality of life.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{Introduction}]{Introduction}\par OPD is the 4 th leading cause of death worldwide and predicted to be third by 2030. In India, COPD accounts for 7\% of deaths and 3\% DALYs loss. \hyperref[b0]{1,}\hyperref[b1]{2} Study was conducted to determine healthseeking behavior \& economic burden of COPD cases and the influence of severity of the disease over the cost of illness and the quality of life of COPD among 35 years \& above rural population of Gurugram, Haryana.\par II. \section[{Methodology}]{Methodology}\par The study was conducted among field practice area of PHC Garhi Harsaru of Gurugram for one year from Jan 2018 to Dec 2018. Presuming the prevalence of cases about 7\% among 35 years \& above form previous study \hyperref[b2]{3} , a sample size of the population was calculated using formula n=( Z 1-a/2 ) 2 p (1-p)/d 2 where p is prevalence and relative precision of 10\% with anticipated non-response 10\% . Population of all 14 villages consisting of 7700 households under PHC Garhi Harsaru listed as per 2011 census, and seven villages selected by simple random sampling. Out of these seven villages, 700 households were selected by probability proportion to size (PPS) sampling methods. All the 1434 individuals above 35 years of age found in these households were examined to detect chronic obstructive pulmonary diseases. Case definition was subject suffering from cough with expectoration for three or more months in a year for not less than two years and breathlessness. Spirometry done to confirm the case \& severity of the condition (Gold criteria). \hyperref[b3]{4} A total of 137 cases listed on screening, of which 115 were taken as a confirmed case of COPD as per case definition, spirometry \& pulmonary medicine consultant advice.\par Cost of illness, which included the direct medical and non-medical, and indirect costs, calculated in Indian Rupees from the expenditures of the hospital visits, pharmacotherapy, oxygen therapy given, laboratory tests, diagnostic procedures, physiotherapy and hospitalization due to acute exacerbations. Quality of life (QOL) of all patients of COPD was assessed using St. George's Respiratory Questionnaire (SGRQ) Ver 2.3 after obtaining the necessary permission from the author. \hyperref[b4]{5} Data collected on structured schedule and analyzed using SPSS ver 22. Prior ethical clearance was taken from Institutional Ethical Committee.\par As per the definitions of the GOLD criteria guidelines according to the severity of the disease taken as: \section[{a) Heath seeking behavior}]{a) Heath seeking behavior}\par Among all COPD patients, 87.83\% seeks immediate medical help in case of any breathing discomfort while 12.7\% neglected their ailment \& did not take any medical advice. Of these 46.09\% preferred allopathic, 42.61 \% preferred the Indian system of medicine \& 11.30 \% preferred naturopathy. 36.52\% utilized government system while 6.09\% could go to qualified private doctor, 41.74 depended upon quacks \& 15.65\% chemist store. \section[{b) The economic cost burden of COPD case}]{b) The economic cost burden of COPD case}\par Out of the total costs, highest spent on direct medical costs (91.02\%) and followed by indirect costs (8.98.\%) as depicted in Table {\ref I}. Hospitalizations, associated co-morbidity and length of stay increased the cost. The mean cost spent by the patients with stage II COPD was Rs.3179.62 ± 99.01 per visit to the hospital, stage III was Rs.16414.79 ± 8365.79 and stage IV was Rs.44077.16 ± 15686.21 per visit (Table \hyperref[tab_2]{2}). All the patients suffering from stage I \& II COPD were treated in the outpatient department. Out of 42 patients with stage III COPD, 29 (32.4\%) hospitalized, and 13 (12.4\%) treated in the outpatient department. Sixteen patients with stage IV COPD admitted in the inpatient wards of the Pulmonary Medicine Department. The mean length of hospital stay was found to be 9 ± 1.2 days for stage III patients and 11.75 ± 2.5 days for stage IV patients. As the severity of the disease increased both the length of hospital stay as well as cost burden increased as shown in Table \hyperref[tab_3]{3}. \section[{c) Quality of life of patients with stage III and stage IV COPD}]{c) Quality of life of patients with stage III and stage IV COPD}\par The quality of life of inpatients was evaluated by using SGRQ. Out of 115 patients, 45 were inpatients, of which 29 were with stage III COPD and 16 with stage IV COPD. The mean SGRQ QOL score of the 115 patients was found to be 53.96 ± 10.38. The SGRQ QOL score of the stage III COPD patients was found to be 44.69 ± 9.27 and stage IV patients was 63.24 ± 11.49. As the severity of the disease increased the quality of life of COPD cases significantly decreased (). Cost of the disease negatively correlated with quality of life. As the quality of life declined the cost of illness increased significantly (p < 0.05). IV. \section[{Discussion}]{Discussion}\par COPD represents a high health-care burden worldwide. The increasing prevalence and life long duration of the illness in those affected translates into increased direct and indirect medical expenditures. The findings of the present study shed light on the comprehensive cost expenditure of patients with COPD. The data obtained from this study demonstrated a strong correlation between the total cost incurred by patients for COPD management and the severity of the disease and which is in concordance with those found in international literature. \hyperref[b6]{6,}\hyperref[b7]{7} The present study had demonstrated a positive relation between the presence of co-morbidities and an increase in the cost of illness. This is in consistent with the report given by Mary Geitona et al. which stated that there was a significant correlation between associated co-morbidities and increased cost. \hyperref[b8]{8} \section[{a) Health seeking behavior}]{a) Health seeking behavior}\par In the present study, among all COPD patients, 87.83\% seeks immediate medical help in case of any breathing discomfort while 12.7\% neglected their ailment. Similar findings were reported by Grover et al. from their study. \hyperref[b9]{9} The cost of illness was found to be higher for patients in stages III and IV COPD as these patients were treated with more number of drugs both initially, during follow-up and also had more number of hospital visits due to frequent acute exacerbations, leading to greater use of diagnostic procedures which had also contributed to higher cost of illness.\par The data obtained from the present study had shed light to the cost variables that contributed to the total cost of illness at different stages of COPD. In stage II COPD, biochemical investigations were the most important cost variable. In stage III \& IV, costs of hospitalization, diagnostic procedures, physician and drugs were the most important cost variables. This was due to increase in length of hospital stay and antibiotic usage in severe stages of COPD. A similar report given by Daniel E Hilleman et al. \hyperref[b10]{10} The increase in severity of the disease has a dramatic negative impact on the quality of life of the patients, a significant decrease with an increase in SGRQ score. A multi centre 2-year follow up study by Claudio F Donner demonstrated that repeated exacerbations resulted in a permanent negative impact on health status. \hyperref[b11]{11} Patients with COPD experience poor physical functioning and live with distressing symptoms that require frequent hospitalization due to disease progression. They develop inability to work and may become socially isolated and often depressed. The current study had shown that the cost of illness increased as the quality of life of patients decreased. Quality of life worsened with severity of disease and with exacerbations resulting in more hospitalization and increased cost of treatment. \hyperref[b12]{12,}\hyperref[b13]{13} The focused on the decrease in health-related quality of life with an increase in cost of therapy in COPD. \section[{b) Cost of illness of COPD}]{b) Cost of illness of COPD}\par In the present study the direct cost was found to be 91\% of the total cost. Majority of the amount was spent for hospitalization, laboratory investigations, diagnostic procedures, drugs and practitioner. This is in concordant with other studies. \hyperref[b6]{6,}\hyperref[b13]{13} On an average a patient spent around 15379.1 Rupees per visit to the hospital. The highest being spent for hospitalization (36.2\%) followed by diagnostic procedures (9.8\%), laboratory investigations (9.87\%), for practitioner (9.21\%), morbidity (8\%), drugs (4.4\%) and the rest accounted for 23.5\% ( (Rs.19450). As the disease severity increased, the amount for the illness also increased. The severity of disease highly correlated with cost of illness. Findings are concordant with their separate studies reported by Kallaru et al and Patel et al. \hyperref[b14]{[14]}\hyperref[b15]{[15]}\hyperref[b16]{[16]} c) Quality of life of patients with stage III and stage IV COPD The quality of life of inpatients was evaluated by using SGRQ. The mean SGRQ QOL score of the 115 patients was found to be 53.96 ± 10.38. The SGRQ QOL score of the stage III COPD patients was found to be 44.69 ± 9.27 and stage IV patients was 63.24 ± 11.49. As the severity of the disease increased the quality of life of COPD patients significantly decreased. Cost of the disease negatively correlated with quality of life. Quality of life was similarly found to be severely impaired in COPD patients by various studies. \hyperref[b17]{[17]}\hyperref[b18]{[18]}\hyperref[b19]{[19]} V. \section[{Conclusion}]{Conclusion}\par The study demonstrated that the total cost of illness of COPD patients increased with severity of disease. The Quality of life of the patients decreased with increase in severity of the disease. The drivers of the total cost were found to be hospitalizations and length of stay. Since acute exacerbations are the main cause of hospitalization among COPD patients, strategies to prevent severe exacerbations could be very cost effective and improve the quality of life. By developing strategies to improve patients' awareness on nicotine replacement therapy, adherence to drug therapy and opting for physical rehabilitation, the direct medical and indirect costs can be reduced which in turn will lower the burden of cost of illness of COPD.\begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.7684931506849314\textwidth}P{0.006269757639620653\textwidth}P{0.07523709167544784\textwidth}} \multicolumn{2}{l}{Stage1 (Mild) -EV 1 /FVC<70\%, FEV I > 80}\\ \multicolumn{2}{l}{Stage II (Moderate) -FEV1/FVC < 70\%, 50\% ? FEV1 <}\\ 80\% predicted\tabcellsep \\ \multicolumn{2}{l}{Stage III (Severe) -FEV1/FVC < 70\%, 30\% ? FEV1 <}\\ 50\% predicted\tabcellsep \\ \multicolumn{2}{l}{Stage IV (Very Severe) -FEV1/FVC<70\%, FEV1 < 30\%}\\ \multicolumn{2}{l}{predicted or FEV1<50\% predicted plus chronic}\\ \multicolumn{2}{l}{respiratory failure and having stable co morbidity.}\\ III.\tabcellsep Results\\ \multicolumn{2}{l}{The mean age of the study patients was}\\ \multicolumn{2}{l}{52.56 ± 11.78 years, and 55 (47.83 \%) patients were in the age group of 35-50 years, followed by 21(18.20\%) in 51-60 years and 39 (33.91\%) patients in above 60 years.}\tabcellsep Year 2019\\ \multicolumn{2}{l}{71 (61.74\%) were males \& 44 (38.26\%) were females. Out of total 115 cases, 57(44.8\%) patients were suffering}\tabcellsep 3\\ \multicolumn{2}{l}{from stage I \& II COPD followed by 42 (40\%) patients with stage III COPD and 16 (15.2\%) with stage IV COPD. Existing stable co-morbidities found in 43 patients (40.95\%) of which, treated tuberculosis seen in 15 (14.}\tabcellsep Volume XIX Issue IV Version I\\ \tabcellsep \tabcellsep D D D D ) F\\ \tabcellsep \tabcellsep (\\ \tabcellsep \tabcellsep Medical Research\\ \tabcellsep \tabcellsep Global Journal of\end{longtable} \par \caption{\label{tab_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{1} \par \begin{longtable}{P{0.19374999999999998\textwidth}P{0.1875\textwidth}P{0.396875\textwidth}P{0.07187500000000001\textwidth}} Total Annual expenditure (INR) on COPD\tabcellsep No. of COPD subject (\%)\tabcellsep \multicolumn{2}{l}{Mean expenditure/head}\\ ? 10000\tabcellsep 31 (26.96\%)\tabcellsep Annual direct Cost\tabcellsep = Rs. 13,477/-(91.01\%)\\ 10001-20000\tabcellsep 71 (61.74\%)\tabcellsep \multicolumn{2}{l}{Annual Indirect cost = Rs. 1,327/-(8.99\%)}\\ ?20000\tabcellsep 13 (11.30\%)\tabcellsep \multicolumn{2}{l}{Annual total mean cost = Rs. 14, 804 /-(100\%)}\end{longtable} \par \caption{\label{tab_1}Table 1 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{P{0.04797178130511463\textwidth}P{0.2653439153439153\textwidth}P{0.15740740740740738\textwidth}P{0.1903880070546737\textwidth}P{0.18888888888888888\textwidth}} \tabcellsep \tabcellsep Stage I \& II (n=57)\tabcellsep Stage III (n=42)\tabcellsep Stage IV (n=16)\\ Cost category\tabcellsep Cost drivers\tabcellsep (mean cost in rupees per patient\tabcellsep (mean cost in rupees per patient\tabcellsep (mean cost in rupees per patient per\\ \tabcellsep \tabcellsep per hospital visit)\tabcellsep per hospital visit\tabcellsep hospital visit\\ \tabcellsep Practitioner\tabcellsep 200\tabcellsep 1776.5\tabcellsep 3612.5\\ \tabcellsep Hospitalization\tabcellsep 0\tabcellsep 5897.87\tabcellsep 19450\\ \tabcellsep Laboratory investigations\tabcellsep 1425\tabcellsep 1549.78\tabcellsep 1737.81\\ \tabcellsep Arterial blood gases\tabcellsep 350\tabcellsep 484.04\tabcellsep 743.75\\ \tabcellsep Diagnostic procedures\tabcellsep 375\tabcellsep 2147.34\tabcellsep 2668.75\\ Direct Medical Cost\tabcellsep Pulmonary function tests Drugs Oxygen therapy\tabcellsep 500 113.1 1.78\tabcellsep 500 658.02 27.12\tabcellsep 500 2232.47 70.31\\ \tabcellsep Nebulisation\tabcellsep 42.85\tabcellsep 353.19\tabcellsep 569.68\\ \tabcellsep Nursing charges\tabcellsep 0\tabcellsep 651.38\tabcellsep 1181.25\end{longtable} \par \caption{\label{tab_2}Table 2 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{3} \par \begin{longtable}{P{0.03139204545454546\textwidth}P{0.18110795454545456\textwidth}P{0.19801136363636362\textwidth}P{0.2197443181818182\textwidth}P{0.2197443181818182\textwidth}} Cost category\tabcellsep Stage I (mean cost in rupees per patient per hospital visit)\tabcellsep Stage II (mean cost in rupees per patient per hospital visit)\tabcellsep Stage III (mean cost in rupees per patient per hospital visit)\tabcellsep Stage IV (mean cost in rupees per patient per hospital visit)\\ \tabcellsep 70.0\tabcellsep 1467.85\tabcellsep 13061.29\tabcellsep 31522.77\\ \tabcellsep 20.0\tabcellsep 174.57\tabcellsep 2161.49\tabcellsep 3963.74\\ \tabcellsep 10.0\tabcellsep 0\tabcellsep 342.55\tabcellsep 7121.37\\ \tabcellsep 100\tabcellsep 1642.42\tabcellsep 15565.33\tabcellsep 42607.88\end{longtable} \par \caption{\label{tab_3}Table 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{2} \par \begin{longtable}{} \end{longtable} \par \caption{\label{tab_4}Table 2 )}\end{figure} \backmatter \subsection[{Acknowledgement}]{Acknowledgement} \begin{bibitemlist}{1} \bibitem[Jones]{b4}\label{b4} \textit{}, P W Jones . (Home page on the internet) \bibitem[Thakkar et al. ()]{b17}\label{b17} ‘Chronic obstructive pulmonary diseases. Does sex really matter?’. M Thakkar , K Rohan , N Jain , N Jain , M Sharma . \textit{Lung India} 2011. 28 p. . \bibitem[Miravitlles et al. ()]{b13}\label{b13} ‘Costs of chronic bronchitis and COPD’. Marc Miravitlles , Cristina Murio , Tina Guerrero , Ramon Gisbert . \textit{Chest} 2003. 123 (3) p. . \bibitem[Patel et al. ()]{b9}\label{b9} ‘Economic burden in direct cost of chronic obstructive pulmonary disease at a tertiary care teaching hospital as prospective cohort study’. K Patel , T Lalwani , K Shah . \textit{Indian J Pharmacy Practice} 2014. 7 p. . \bibitem[Patel et al. ()]{b14}\label{b14} ‘Economic burden in direct cost of chronic obstructive pulmonary disease at a tertiary care teaching hospital as prospective cohort study’. K Patel , T Lalwani , K Shah . \textit{Indian J Pharmacy Practice} 2014. 7 p. . \bibitem[Seemungal et al. ()]{b12}\label{b12} ‘Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease’. T A Seemungal , G C Donaldson , E A Paul , J C Bestall , D J Jeffries , J A Wedzicha . \textit{Am J Respir Crit Care Med} 1998. 157 (5) p. . \bibitem[Jindal ()]{b2}\label{b2} ‘Emergence of chronic obstructive disease as an epidemic in India’. S Jindal . \textit{Indian J Med Res} 2006. 124 p. . \bibitem[Halbert et al. ()]{b0}\label{b0} ‘Global burden of COPD: systematic review and meta analysis’. R J Halbert , J L Natoli , A Gano , E Badamgarav , A S Buist , D Mannino . \textit{Euro Respri J} 2006. 28 p. . \bibitem[Ahmed et al. ()]{b20}\label{b20} \textit{Health related quality of life of chronic obstructive pulmonary diseases patients: Results from community based cross section study in Aligarh}, M A Ahmed , A Neyaz , A Aslam . 2016. UP, India. Lung India. p. . \bibitem[Kallaru et al. ()]{b6}\label{b6} ‘impact of severity of disease on cost of illness and quality of life of patients with COPD’. H Kallaru , V Nagasubramanian , H Balakrishnan , K Gopal , T Palani . \textit{J Young Pharmacists} 2015. 7 p. . \bibitem[Geitona and Hatzikou ()]{b8}\label{b8} ‘Paschalis Steiropoulos, Evangelos Alexopoulos C, Demosthenes Bouros. The cost of COPD exacerbations: A university hospital -based study in Greece’. Mary Geitona , Magdalini Hatzikou . \textit{Respiratory Med} 2010. 105 (3) p. . \bibitem[Miravitlles et al. ()]{b15}\label{b15} ‘Pharmacoeconomic Evaluation of acute exacerbations of chronic bronchitis and COPD’. Marc Miravitlles , Cristina Murio , Tina Guerrero , Ramon Gisbert . \textit{Chest} 2002. 121 (5) p. . \bibitem[Daniel Hilleman et al. ()]{b10}\label{b10} ‘Pharmacoeconomic evaluation of COPD’. E Daniel Hilleman , Naresh Dewan , Mark Maleskar , Mitchell Friedmann . \textit{Chest} 2000. 118 (5) p. . \bibitem[Donner et al. ()]{b11}\label{b11} ‘Pharmacoeconomics in COPD and inappropriateness of diagnostics, management and treatment’. Claudio Donner , F , Johann Christian Virchow , Mirco Vusuardi . \textit{Respiratory Med} 2011. 105 (6) p. . \bibitem[Pocket guide to COPD diagnosis, management and prevention. A guide for health care professionals 2017 ()]{b3}\label{b3} \textit{Pocket guide to COPD diagnosis, management and prevention. A guide for health care professionals 2017}, 2017. p. 2. (Report Global) (Global initiative of chronic obstructive lung diseases) \bibitem[Mckay et al. ()]{b1}\label{b1} ‘Prevalence of COPD in India: a systematic review’. A J Mckay , P A Mahesh , J Z Fordham , A Majeed . \textit{Prim Care Respir J} 2012. 21 p. . \bibitem[Shahab et al. ()]{b7}\label{b7} ‘Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary diseases in a naturally representative population sample’. L Shahab , M Jarvis , J Britton , R West . \textit{Thorax} 2006. 61 p. . \bibitem[Zamzam et al. ()]{b19}\label{b19} ‘Quality of life in COPD patients’. M A Zamzam , N Y Arab , R A Wahsh , A Z Ragab , E M Allam . \textit{Eqyptian J Chest Dis TB} 2012. 4 p. . \bibitem[Jamal Alomar ()]{b18}\label{b18} ‘Risk Assessment for COPD Using CAT Questionnaire and Vitalograph COPD-6 Screening Device’. Muaed Jamal Alomar , D . \textit{J Young Pharmacists} 2014. 6 (2) p. . \bibitem[St George's respiratory questionnaire Manual (2014)]{b5}\label{b5} \textit{St George's respiratory questionnaire Manual}, 2014 February 20. 2014 May 15. \bibitem[Ramsey and Sullivan ()]{b16}\label{b16} ‘The burden of illness and economic evaluation for COPD’. S D Ramsey , S Sullivan . \textit{European Respiratory Journal} 2003. 21 (41) p. . \end{bibitemlist} \end{document}